Product Description
The research-grade biosimilar is a humanized IgG1 monoclonal antibody that specifically targets the p19 subunit of IL-23 and thereby inhibits the interaction with the IL-23 receptor. IL-23 is a cytokine that plays an important role in mediating inflammatory and immune responses. Binding of the antibody to Il-23 blocks the release of pro-inflammatory cytokines and chemokines associated with psoriasis. The original drug received approval from the FDA in 2018 to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic and phototherapy
Biovision | A2159 | Anti-IL-23? (Tildrakizumab), Humanized Antibody DataSheet
Antibody Target: IL-23?
Target Alternative Name: MK-3222, SCH 900222, P19, SGRF, IL-23, IL23A, IL23P19
Tag Line: The biosimilar is a humanized monoclonal antibody that specifically targets IL-23 p19 subunit and inhibits the release of cytokines and chemokines involved in mediating inflammation in psoriasis
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human IL-23?
Accession #: DB14004
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE